Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda

被引:41
作者
Meiser, Bettina [1 ,2 ]
Tucker, Kathy [1 ]
Friedlander, Michael [1 ,2 ]
Barlow-Stewart, Kristine [3 ]
Lobb, Elizabeth [4 ,5 ,6 ]
Saunders, Christobel [7 ]
Mitchell, Gillian [8 ]
机构
[1] Prince Wales Hosp, Dept Med Oncol, Randwick, NSW 2031, Australia
[2] Univ New S Wales, Prince Wales Clin Sch, Randwick, NSW 2031, Australia
[3] Royal N Shore Hosp, Ctr Genet Educ, St Leonards, NSW 2065, Australia
[4] Univ Sydney, Ctr Med Psychol & Evidence Based Decis Making, Sydney, NSW 2006, Australia
[5] Curtin Univ Technol, WA Ctr Canc & Palliat Care, Bentley, WA 6102, Australia
[6] Edith Cowan Univ, WA Ctr Canc & Palliat Care, Joondalup, WA 6027, Australia
[7] Univ Western Australia, Sch Surg, Nedlands, WA 6009, Australia
[8] Peter MacCallum Canc Inst, Jack Brockhoff Familial Canc Ctr, Melbourne, Vic 3002, Australia
基金
英国医学研究理事会;
关键词
D O I
10.1186/bcr2194
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Many women newly diagnosed with breast cancer and with a strong family history of breast cancer are referred to a family cancer service for genetic counselling and for consideration of genetic testing for germline mutations in cancer predisposition genes following completion of their cancer treatment. However, there is growing evidence that mutation status may influence treatment recommendations, and that there may be benefits in having 'treatment-focused genetic counselling and testing' available shortly after cancer diagnosis. This article reviews the literature that could inform the development of treatment-focused genetic counselling and testing, including: the rationale for genetic testing to aid with treatment decisions; the potential benefits of using mutation or risk status to tailor management; the criteria that may be used to identify patients most likely to carry germline mutations; and the evidence regarding women's decision-making regarding treatment-focused genetic counselling and testing and the associated psychological impact.
引用
收藏
页数:14
相关论文
共 98 条
  • [1] Abeliovich D, 1997, AM J HUM GENET, V60, P505
  • [2] [Anonymous], 2008, J CLIN ONCOLOGY M S, DOI DOI 10.1200/JCO.2008.26.15_SUPPL.5510
  • [3] Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40
    Ardern-Jones, A
    Kenen, R
    Eeles, R
    [J]. EUROPEAN JOURNAL OF CANCER CARE, 2005, 14 (03) : 272 - 281
  • [4] Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer
    Atchley, Deann P.
    Albarracin, Constance T.
    Lopez, Adriana
    Valero, Vicente
    Amos, Christopher I.
    Gonzalez-Angulo, Ana Maria
    Hortobagyi, Gabriel N.
    Arun, Banu K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (26) : 4282 - 4288
  • [5] *AUSTR CANC NETW, 1999, GUID FAM ASP CANC
  • [6] Contribution of BRCAI and BRCA2 germ-line mutations to the incidence of breast cancer in young women:: Results from a prospective population-based study in France
    Bonadona, V
    Sinilnikova, OM
    Chopin, S
    Antoniou, AC
    Mignotte, H
    Mathevet, P
    Brémond, A
    Martin, A
    Bobin, JY
    Romestaing, P
    Raudrant, D
    Rudigoz, RC
    Léoné, M
    Chauvin, F
    Easton, DF
    Lenoir, GM
    Lasset, C
    [J]. GENES CHROMOSOMES & CANCER, 2005, 43 (04) : 404 - 413
  • [7] Bonadona V, 2002, CANCER EPIDEM BIOMAR, V11, P97
  • [8] American Society of Clinical Oncology policy statement update: Genetic testing for cancer susceptibility
    Bruinooge, SS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) : 2397 - 2406
  • [9] Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients
    Choi, DH
    Lee, NH
    Bale, AE
    Carter, D
    Haffty, BG
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) : 1638 - 1645
  • [10] Tailoring breast cancer treatment to genetic status: The challenges ahead
    Daly, MB
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (10) : 1776 - 1777